• Biovica will hold an extra general meeting in Stockholm on Sept. 30, 2026.
• Shareholders will vote on approving a rights issue of up to 97,303,733 B shares at SEK 0.30 each, raising up to SEK 29.19 million.
• The meeting will also consider a directed issue of up to 7,071,112 B shares at SEK 0.30, to HDF Cancer Monitoring BV.
• The directed issue is intended to settle an underwriting fee of up to SEK 2.12 million via set-off.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.